JP7840851B2 - Ｅｎｌ／ａｆ９ ｙｅａｔｓの阻害剤 - Google Patents

Ｅｎｌ／ａｆ９ ｙｅａｔｓの阻害剤

Info

Publication number
JP7840851B2
JP7840851B2 JP2022538193A JP2022538193A JP7840851B2 JP 7840851 B2 JP7840851 B2 JP 7840851B2 JP 2022538193 A JP2022538193 A JP 2022538193A JP 2022538193 A JP2022538193 A JP 2022538193A JP 7840851 B2 JP7840851 B2 JP 7840851B2
Authority
JP
Japan
Prior art keywords
mmol
methyl
alkyl
equivalent
resulting solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527487A (ja
JP2023527487A5 (cg-RX-API-DMAC10.html
Inventor
エイ． カン，タンウィアー
リバトン，ナイジェル
フカセ，ヨシユキ
ミチノ，マヤコ
ダブリュー． スタンフォード，アンドリュー
ダブリュー． ミラー，マイケル
ハギンズ，デーヴィッド
マインキー，ピーター
アリス，シー．デーヴィッド
ワン，リリン
ヴァッカ，ジョーセフ
ラドゥワエティ，タミー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bridge Medicines LLC
Original Assignee
Bridge Medicines LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Medicines LLC filed Critical Bridge Medicines LLC
Publication of JP2023527487A publication Critical patent/JP2023527487A/ja
Publication of JP2023527487A5 publication Critical patent/JP2023527487A5/ja
Application granted granted Critical
Publication of JP7840851B2 publication Critical patent/JP7840851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022538193A 2019-12-17 2020-12-17 Ｅｎｌ／ａｆ９ ｙｅａｔｓの阻害剤 Active JP7840851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949160P 2019-12-17 2019-12-17
US62/949,160 2019-12-17
PCT/US2020/065593 WO2021127166A1 (en) 2019-12-17 2020-12-17 Inhibitors of enl/af9 yeats

Publications (3)

Publication Number Publication Date
JP2023527487A JP2023527487A (ja) 2023-06-29
JP2023527487A5 JP2023527487A5 (cg-RX-API-DMAC10.html) 2025-05-22
JP7840851B2 true JP7840851B2 (ja) 2026-04-06

Family

ID=76476792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538193A Active JP7840851B2 (ja) 2019-12-17 2020-12-17 Ｅｎｌ／ａｆ９ ｙｅａｔｓの阻害剤

Country Status (14)

Country Link
US (1) US20230027198A1 (cg-RX-API-DMAC10.html)
EP (1) EP4076440B1 (cg-RX-API-DMAC10.html)
JP (1) JP7840851B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220129554A (cg-RX-API-DMAC10.html)
CN (2) CN120289456A (cg-RX-API-DMAC10.html)
AU (1) AU2020407589A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022012273A2 (cg-RX-API-DMAC10.html)
CA (1) CA3162253A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022009852A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220326A (cg-RX-API-DMAC10.html)
IL (1) IL293839A (cg-RX-API-DMAC10.html)
MX (1) MX2022007442A (cg-RX-API-DMAC10.html)
PH (1) PH12022551529A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021127166A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518824A (ja) 2021-05-13 2024-05-07 ブリッジ メディシンズ Ｅｎｌ／ａｆ９ ｙｅａｔｓのｃ結合阻害剤
CN117580944A (zh) * 2021-08-03 2024-02-20 苏州沙砾生物科技有限公司 一种修饰的免疫细胞及其用途
US20250376473A1 (en) * 2022-07-01 2025-12-11 Cytosinlab Therapeutics Co., Ltd. Prmts inhibitor and use thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
US20260078121A1 (en) * 2022-09-08 2026-03-19 Bridge Medicines Inhibitors of enl/af9 yeats and flt3
WO2024140923A1 (zh) * 2022-12-30 2024-07-04 苏州浦合医药科技有限公司 Prmt5-mta抑制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083804A1 (ja) 2010-01-06 2011-07-14 武田薬品工業株式会社 インドール誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2375359C2 (ru) * 2004-09-03 2009-12-10 Юхан Корпорейшн ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-c]ПИРИДИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US20110015225A1 (en) * 2008-04-01 2011-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
WO2022146920A1 (en) * 2020-12-28 2022-07-07 Celgene Corporation Heterocyclic compounds and their use for parasitic diseases
JP2024518824A (ja) * 2021-05-13 2024-05-07 ブリッジ メディシンズ Ｅｎｌ／ａｆ９ ｙｅａｔｓのｃ結合阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083804A1 (ja) 2010-01-06 2011-07-14 武田薬品工業株式会社 インドール誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2019年，Vol. 10，pp. 1661-1666
Angewandte Chemie International Edition，2018年，Vol. 57，pp. 16302-16307
Journal of Medicinal Chemistry，2018年，Vol. 61，pp. 10929-10934
SLAS Discovery，2019年，Vol. 24，pp. 133-141

Also Published As

Publication number Publication date
JP2023527487A (ja) 2023-06-29
CA3162253A1 (en) 2021-06-24
CN115427035B (zh) 2025-04-22
CO2022009852A2 (es) 2022-10-11
MX2022007442A (es) 2023-02-13
EP4076440A1 (en) 2022-10-26
US20230027198A1 (en) 2023-01-26
EP4076440B1 (en) 2026-07-08
IL293839A (en) 2022-08-01
KR20220129554A (ko) 2022-09-23
CR20220326A (es) 2023-02-10
PH12022551529A1 (en) 2024-02-05
CN115427035A (zh) 2022-12-02
WO2021127166A1 (en) 2021-06-24
AU2020407589A1 (en) 2022-07-21
EP4076440A4 (en) 2023-11-08
CN120289456A (zh) 2025-07-11
BR112022012273A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
JP2023527487A (ja) Ｅｎｌ／ａｆ９ ｙｅａｔｓの阻害剤
KR102049534B1 (ko) 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
AU2018285131B2 (en) Heteroaromatic compounds as Vanin inhibitors
KR102514914B1 (ko) 카르바졸 유도체
KR20240047955A (ko) Enl/af9 yeats의 c-연결된 억제제
WO2016100166A1 (en) SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
AU2012295802A1 (en) Tricyclic heterocyclic compounds and JAK inhibitors
AU2020380828A1 (en) WDR5 inhibitors and modulators
CN107207504A (zh) 酞嗪酮衍生物、其制备方法及用途
WO2023077070A1 (en) Rxfp1 agonists
WO2008100618A2 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
EP4583869A2 (en) Inhibitors of enl/af9 yeats and flt3
JP2023526424A (ja) ムスカリン性アセチルコリン受容体ｍ５の競合及び非競合阻害剤
WO2024175065A1 (zh) 一类含有芳基取代的cdk12/13的降解剂，及其制备方法、药物组合物和应用
CN112759588B (zh) 苯并五元杂环胺类衍生物及其用途
WO2025235367A1 (en) Azaindolinone compounds as kca3.1 potassium channel blockers
CN120813585A (zh) 稠合双环化合物及其作为mer和axl抑制剂的用途
KR20190132703A (ko) 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
HK1238642B (en) Carbazole derivatives
HK1238642A1 (en) Carbazole derivatives

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250213

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260325

R150 Certificate of patent or registration of utility model

Ref document number: 7840851

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150